2 citations
,
September 2023 in “Curēus” This study reported that topical spironolactone improved lid margin vascularity, corneal fluorescein staining, and disease severity scores in patients with ocular graft-versus-host disease, suggesting a potential therapeutic role by enhancing corneal lipid production with minimal adverse effects.
1 citations
,
August 2022 in “Journal of Cosmetic Dermatology” This study found that combining 5% topical minoxidil and 5% topical spironolactone solutions may enhance treatment efficacy for androgenetic alopecia in both men and women, with significant reductions in vellus hair.
1 citations
,
June 2023 in “Cureus” In a retrospective study, researchers found that topical spironolactone improved tear film quality and reduced inflammation related to meibomian gland dysfunction and evaporative dry eye in patients, demonstrating good tolerability and suggesting it as a potential therapy for managing the condition.
August 2023 in “Journal of Cosmetic Dermatology” This study found that combining minoxidil and spironolactone was more effective for hair density and severity of hair loss in women with androgenic alopecia compared to minoxidil and finasteride, with no serious adverse effects reported.
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” This study concluded that both oral and topical spironolactone effectively treat androgenetic alopecia, with topical administration being safer and suitable for any gender, especially when combined with minoxidil.